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PCLINICAL RESEARCH Atheroma Composition and Metabolic Syndrome
Impact of Metabolic Syndrome on Tissue Characteristics
of Angiographically Mild to Moderate Coronary Lesions
Integrated Backscatter Intravascular Ultrasound Study
Tetsuya Amano, MD, PHD,* Tatsuaki Matsubara, MD, PHD,† Tadayuki Uetani, MD, PHD,*
Michio Nanki, MD, PHD,* Nobuyuki Marui, MD, PHD,* Masataka Kato, MD,* Kosuke Arai, MD,*
Kiminobu Yokoi, MD,* Hirohiko Ando, MD,* Hideki Ishii, MD,‡ Hideo Izawa, MD, PHD,‡
Toyoaki Murohara, MD, PHD‡
Nagoya, Japan
Objectives We assessed the impact of metabolic syndrome (MetS) on the tissue characteristics of coronary plaques using
integrated backscatter intravascular ultrasound (IB-IVUS).
Background Metabolic syndrome is associated with the increasing risk of cardiovascular disease.
Methods We identified MetS by the definition of the National Cholesterol Education Program in Adult Treatment Panel III
criterion. Non-target coronary lesions with mild to moderate stenosis were measured by conventional and IB-
IVUS parameters using 40-MHz (motorized pullback 0.5 mm/s) intravascular catheter. A total of 20 IB-IVUS im-
ages were recorded at an interval of 0.5 mm for 10 mm length in each plaque. The 3-dimensional analyses
were performed using commercially available software.
Results The prevalence of MetS was 61 patients (50%) with 73 lesions (49%) among 122 patients with 148 lesions.
Patients with MetS showed a significant increase in percentage lipid area (38  19% vs. 30  19%, p  0.02)
and percentage lipid volume (39  17% vs. 33  17%, p  0.03), and they also showed a significant decrease
in percentage of fibrous volume (57  14% vs. 61  13%, p  0.03). Multivariate regression analysis after ad-
justment for potentially confounding risk factors showed that MetS remains correlated independently with the
percentage of lipid volume (r  0.223, p  0.01). Logistic regression analysis after adjusting for confounding
and non-MetS coronary risk factors showed that MetS (odds ratio 4.00, 95% confidence interval 1.33 to 12.0,
p  0.01) is proved to be an independent predictor of the lipid-rich plaque.
Conclusions Metabolic syndrome is associated with lipid-rich plaques, contributing to the increasing risk of plaque
vulnerability. (J Am Coll Cardiol 2007;49:1149–56) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.028c
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petabolic syndrome (MetS) is characterized by the concur-
ence of cardiovascular disease (CVD) risk factors: impaired
lucose tolerance, obesity, dyslipidemia, and hypertension.
ecent epidemiologic studies have showed that MetS is an
ncreasing risk factor for CVD (1,2). On the other hand, it
as been reported (3,4) that disruption or erosion of
ulnerable plaques and subsequent thrombosis are the most
requent causes of acute coronary syndrome (ACS) and that
he culprit coronary lesion in ACS shows a relatively minor
tenosis, 50% of the reference diameter (5,6). Further-
ore, postmortem studies have identified several histologic
rom the *Department of Cardiology, Chubu-Rosai Hospital, Nagoya, Japan;
Department of Internal Medicine, School of Dentistry, Aichi-Gakuin University,
agoya, Japan; and ‡Department of Cardiology, Nagoya University Graduate School
f Medicine, Nagoya, Japan.r
Manuscript received August 31, 2006; revised manuscript received October 30,
006, accepted November 6, 2006.haracteristics of these vulnerable plaques, such as greater
laque burdens and greater lipid area (7). Intravascular
ltrasound allows cross-sectional imaging of coronary arter-
es and provides more comprehensive assessment of athero-
clerotic plaque in vivo. Recently, Kawasaki et al. (8) have
eveloped an integrated backscatter intravascular ultrasound
IB-IVUS), which allows analyzing tissue components of
oronary plaque in vivo and shows that vulnerable plaques
aused by ACS are relevant to increase in plaque burden,
ncluding greater lipid pool (9). Regarding the association of
etS with vessel atherosclerosis, several studies have shown
hat the individual components of MetS are related to
easurements of subclinical atherosclerosis such as carotid
ntima-media thickness (10,11). Few studies, however, have
xamined the relevance of MetS as an entity with coronary
laque, especially with its tissue components. To assess the
elevant detail of MetS and coronary plaque morphology is
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Metabolic Syndrome and Plaque Characteristics March 20, 2007:1149–56more important from a preven-
tion perspective. In the present
study using IB-IVUS, we as-
sessed the impact of MetS on
tissue characteristics with mild to
moderate coronary lesions in pa-
tients with CVD, taking into
account possible confounding
factors.
Methods
Patients and study design. This
study was a prospectively planned
observational study for non-target
coronary lesions with mild to
moderate stenosis (percentage di-
ameter stenosis 50%) in patients
with angina pectoris recruited to
undergo an elective percutaneous
coronary intervention (PCI). Pa-
tients with acute myocardial in-
farction (AMI) were excluded.
Intravascular ultrasound was per-
formed on 126 consecutive pa-
tients with 154 coronary arteries
between September 2005 and Au-
gust 2006. Unstable angina pecto-
ris (UAP) was defined as either
angina with a progressive cre-
scendo pattern or angina that oc-
curred at rest. Various lipid and
inflammatory profiles were mea-
sured by commercial radioimmu-
noassay kits and specific immuno-
radiometric assays. For this
purpose, blood samples were col-
ected from patients before PCI in a 10- to 12-h overnight fast.
CA analysis and IVUS procedure. Before performance
f coronary angiography and PCI, patients were adminis-
ered an intracoronary 0.5 mg of isosorbide dinitrate to
revent coronary spasm. Online quantitative coronary an-
iography (QCA) analysis was conducted, and reference
iameter and percentage diameter stenosis were measured
y a validated automated edge-detection program (CMS-
EDIS Medical Imaging System, Leiden, the Nether-
ands). Analysis segments, vessels narrowing at 50% for
eference diameter, were selected with QCA by 2 indepen-
ent observers unaware of the clinical data. Another coro-
ary artery was analyzed when the selected segments by
CA were 20 mm from the target site of PCI and when
he IVUS catheter would not cross the lesion because of
evere stenosis. Intravascular ultrasound was performed to 1
r 2 arterial segments of each patient. A personal computer
quipped with custom software (IB-IVUS, YD Co., Ltd.,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
ATP  Adult Treatment
Panel
CSA  cross-sectional area
CVD  coronary vessel
disease
EEM  external elastic
membrane
%FV  percentage of
fibrous volume
IB-IVUS  integrated
backscatter intravascular
ultrasound
IVUS  intravascular
ultrasound
LCSA  lumen cross-
sectional area
%LV  percentage of lipid
volume
MetS  metabolic
syndrome
NCEP  National
Cholesterol Education
Program
PCI  percutaneous
coronary intervention
QCA  quantitative
coronary angiography
3D  three-dimensional
UAP  unstable angina
pectorisara, Japan) was connected to the IVUS imaging system aClear View, Boston Scientific, Natick, Massachusetts) to
btain radio frequency signal output, signal trigger output,
nd video image output. Ultrasound backscattered signals
ere acquired using a 40 MHz (motorized pullback 0.5
m/s) mechanically rotating IVUS catheter in order to be
igitized and subjected for spectral analysis. Integrated
ackscatter values for each tissue component were calculated
s an average power using a fast Fourier transform, mea-
ured in decibels (dB), of the frequency component of
ackscattered signal from a small volume of tissue (8,9). A
otal of 20 IB-IVUS images were captured at an interval of
.5 mm for 10 mm length at each plaque.
easurements of conventional and IB-IVUS parameters.
n the conventional IVUS analysis, cross-sectional images
ere quantified for lumen cross-sectional area (LCSA),
xternal elastic membrane (EEM), cross-sectional area
CSA), and plaque (P)  media (M) cross-sectional area
P M CSA  EEM CSA  LCSA) using software built
n the IVUS system. Eccentricity index of P  M was
alculated as: (maximum P  M thickness  minimum
M thickness)/maximum PM thickness. Remodeling
ndex was defined as a ratio of EEM CSA at the measured
esion (minimum luminal site) to reference EEM CSA
average of the proximal and distal reference segments). The
ccentricity index and the remodeling index were calculated
n the segment with minimal luminal area. The percentage
f fibrous area (fibrous area/plaque area, %FA) and the
ercentage lipid area (lipid area/plaque area, %LA) were
utomatically calculated by the IB-IVUS system. The per-
entage of high signal area (a part of the calcification on the
nner surface that could be measured with the formula of
B-IVUS/plaque area) was also automatically calculated by
B-IVUS as a high-signal area. Thrombus formation could
ot be differentiated and may, if present, have been included
n IB-IVUS images. The technique described has not yet
een modified to visualize mural or occlusive thrombus
ormation. Conventional 3-dimensional (3D) IVUS image
nalysis was conducted using commercially available soft-
are (TapeMeasure/EchoPlaque, Indec System, Mountain
iew, California). After digitalization of IVUS recordings
t a frame rate of 30 images/s, longitudinal views of the
tudied segments were automatically processed by the sys-
em. The EEM CSA and LCSA were manually traced at
6-frame intervals, and interpolated measurements of the
emaining frames were automatically generated. Then vessel
olume, lumen volume, and total plaque volume were
alculated. Three-dimensional analysis for IB-IVUS images
as performed to fibrous volume, lipid volume, and high
ignal volume (sum of fibrous, lipid, and high signal area in
ach CSA at 0.5 mm axial intervals for the 20 IB-IVUS
mages, respectively). Then the percentage of fibrous vol-
me (fibrous volume/plaque volume, %FV), lipid volume
lipid volume/plaque volume, %LV), and high signal vol-
me (high signal volume/plaque volume) were calculated.
he representative 3D color-coded maps of the coronaryrtery plaques in patients with or without MetS were also
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March 20, 2007:1149–56 Metabolic Syndrome and Plaque Characteristicsonstructed as previously reported (12). In brief, the 3D IB
VUS color-coded maps consecutively connecting 20 im-
ges were digitized every 0.5 mm, and the number of voxels
f lipid pool was automatically measured. The IVUS mea-
urements were conducted independently by 2 physicians
ho did not recognize patient characteristics. The variabil-
ty of %LV and %FV determined by 2 physicians was also
onsidered from 30 randomly selected records.
efinitions of MetS and coronary risk factors. Metabolic
yndrome was defined by following criteria of the National
holesterol Education Program (NCEP) in Adult Treat-
ent Panel (ATP) III (13) and patients with 3 or more of
he following criteria: 1) waist circumference (WC)90 cm
n women or 85 cm in men; 2) high-density lipoprotein
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
MetS ()
(n  61)
MetS ()
(n  61) p Value
Male 44 (72) 35 (57) 0.09
Age, yrs 69 9 70 8 0.65
Ejection fraction, % 65 12 66 12 0.75
Clinical history
Hypertension 52 (85) 30 (49) 0.001
Diabetes mellitus 46 (75) 24 (39) 0.001
Current smoker 23 (38) 15 (25) 0.12
Unstable angina pectoris 10 (16) 11 (18) 0.81
Old myocardial infarction 14 (23) 9 (15) 0.25
Previous PCI 14 (23) 11 (18) 0.51
Previous CABG 4 (7) 3 (5) 0.70
Coronary artery disease
Multiple vessel 32 (53) 31 (51) 0.86
Target plaque location
Left anterior descending 37 (51) 38 (51) 0.99
Left circumflex 10 (14) 12 (16) 0.70
Right 26 (35) 25 (33) 0.77
Blood lipid levels, mg/dl
Total cholesterol 202 34 191 39 0.09
Triglycerides 181 88 109 73 0.001
HDL cholesterol 43 12 51 13 0.001
LDL cholesterol 122 28 116 30 0.25
C-reactive protein, mg/dl 0.42 0.75 0.26 0.54 0.17
Medication
Aspirin 58 (95) 60 (98) 0.31
Ticlopidine 44 (72) 48 (79) 0.40
Statins 36 (59) 37 (61) 0.86
Fibrates 3 (5) 2 (3) 0.65
Angiotensin-converting
enzyme inhibitors
12 (20) 10 (16) 0.64
Angiotensin II type 1
receptor antagonists
25 (41) 22 (36) 0.58
Nitrates 28 (46) 29 (48) 0.86
Calcium-channel
blockers
32 (53) 25 (41) 0.21
Beta-blockers 35 (57) 31 (51) 0.47
Pioglitazone 7 (11) 4 (7) 0.35
Insulin 10 (16) 6 (10) 0.29
alues are mean  SD or number of patients (%).n
CABG  coronary artery bypass graft; HDL  high-density lipoprotein; LDL  low-density
ipoprotein; MetS  metabolic syndrome; PCI  percutaneous coronary intervention.holesterol 40 mg/dl; 3) serum triglycerides 150 mg/dl;
) known hypertensives or blood pressure130/85 mm Hg;
nd 5) fasting glucose 110 mg/dl. The cutoff values for
C were modified with the values used in Japanese
opulations (14). Diabetes mellitus was defined as using any
nti-hyperglycemic medication and was counted as meeting
he glucose criterion. Patients taking antihypertensive med-
cation were not counted as meeting the blood pressure
riterion because many CVD patients with normal blood
ressure were receiving beta-blockers or calcium-channel
ntagonists to control angina, or they were receiving
ngiotensin-converting enzyme inhibitors to decrease car-
iovascular risk. Smoking status was defined as current or
uit within a year at baseline. All patients were given
nformed consent, and the study was approved by the
ommittee for Human Investigation of the investigator’s
nstitution.
tatistical analysis. Statistical analysis was performed by
he SAS statistical software package (version 8.02, SAS
nstitute, Inc., Cary, North Carolina). Continuous and
ategorical variables were expressed as mean  SD and
roportions, respectively. Univariate analysis was applied to
ompare clinical, laboratory, and ultrasound parameters
etween MetS and non-MetS, by use of chi-square test and
isher exact tests when appropriate for categorical variables
nd by unpaired Student t test for continuous normally
istributed variables and Mann-Whitney U tests for non-
ata for Quantitative Coronaryngiography and Intravascular Ultrasound
Table 2 Data for Quantitative CoronaryAngiography and Intravascular Ultrasound
MetS ()
(n  73)
MetS ()
(n  75) p Value
QCA analysis
Reference diameter, mm 2.7 0.6 2.7 0.6 0.53
Diameter stenosis, % 24 9 22 7 0.43
Conventional IVUS analysis
Vessel area, mm2 12.2 4.5 11.1 3.8 0.12
Lumen area, mm2 4.8 2.4 4.5 2.2 0.44
Plaque area, mm2 7.5 3.8 6.7 2.9 0.15
Plaque burden, % 60 16 60 13 0.98
Eccentricity index 0.63 0.13 0.62 0.18 0.72
Remodeling index 0.94 0.13 0.92 0.12 0.36
Vessel volume, mm3 132.7 51.5 118.9 40.2 0.07
Lumen volume, mm3 66.6 30.7 61.2 25.4 0.24
Plaque volume, mm3 66.1 32.7 57.7 25.1 0.08
Plaque volume, % 49 13 48 12 0.77
IB IVUS analysis
Fibrous area, % 58 16 62 15 0.06
Lipid area, % 38 19 30 19 0.02
High signal area, % 5 5 7 8 0.08
Fibrous volume, % 57 14 61 13 0.03
Lipid volume, % 39 17 33 17 0.03
High signal volume, % 5 5 6 5 0.17
alues are mean  SD. Data for the percentage diameter stenosis and for cross-sectional area
nalysis were calculated at the site of minimum luminal area.
IB  integrated backscatter; IVUS  intravascular ultrasound; MetS  metabolic syndrome;
CA  quantitative coronary angiography.ormally distributed variables. To account for repeated
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Metabolic Syndrome and Plaque Characteristics March 20, 2007:1149–56ssessments to one patient, generalized estimation equations
GEE) linear regression (for continuous outcomes) or GEE
ogistic regression (for binary outcomes) was performed to
stimate corrected probability values. In the present study,
e performed a receiver operating characteristic curve anal-
sis to assess the optimal cutoff values of %LV and %FV for
he prediction of UAP. The lipid-rich plaque was defined as
oth an increase in %LV (52%) and a decrease in %FV
47%). We used linear regression analysis to examine the
elationship of MetS with %LV and %FV adjusting for
onfounding (age, gender, and body mass index) and various
on-MetS risk factors (smoking, low-density lipoprotein
LDL] cholesterol, multivessel disease, and history of old
yocardial infarction). Logistic regression analysis was ap-
lied to study for best predictors of the lipid-rich plaque
fter adjusting for confounding and various risk factors.
nivariate predictors of %LV or %FV with a p value 0.2
ere also entered into the model. Three groupings of
ndividual components of MetS (risk 0 to 2, 3, and 4 to 5)
Figure 1 Representative Images of Conventional Intravascular
Backscatter Intravascular Ultrasound Color-Coded Ma
(A) Patients with () metabolic syndrome (MetS); (B) patients without () MetS. T
were 46.1% and 50.1% in panel A, and 12.1% and 80.9% in panel B, respectivelyere evaluated using analysis of variance. Bonferroni test for
ultiple comparisons to determine their associations with
he lipid-rich plaque rate was used with analysis of variance.
p value 0.05 was considered statistically significant.
esults
tudy populations and baseline characteristics. One
undred and twenty-two patients with 148 angina-
nrelated coronary lesions (a total of 2,960 IB-IVUS im-
ges) were evaluated in the present study. Four patients
2 patients with MetS) were excluded because IB-IVUS
ata were not available. The prevalence of MetS was 61
atients (50%), with 73 lesions (49%) among these patients.
he mean values of continuous variables with normal
istribution, including age, ejection fraction, total choles-
erol, LDL cholesterol, and high-density lipoprotein cho-
esterol were compared between the 2 groups by use of
npaired Student t test. Mann-Whitney U tests were used
sound and 2-Dimensional Integrated
Coronary Artery Plaques in Patients With or Without MetS
rcentage of lipid area and the percentage of fibrous area
 lipid pool; green yellow  fibrous lesion; red  high signal lesion.Ultra
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March 20, 2007:1149–56 Metabolic Syndrome and Plaque Characteristicso evaluate differences in triglycerides and C-reactive pro-
ein. The frequency of gender, hypertension, diabetes mel-
itus, smoking, unstable angina pectoris, old myocardial
nfarction, previous PCI, previous coronary artery bypass
raft, multi-vessel disease, target plaque location, and med-
cation therapy was compared between the groups by chi-
quare analysis.
There were no significant differences between the groups
xcept for the MetS components (Table 1).
uantitative parameters of QCA and IVUS. In the
CA and IVUS parameters, vessel volume and plaque
olume were compared between the 2 groups by the
ann-Whitney U test and the other parameters by un-
aired Student t test. Table 2 shows quantitative QCA and
VUS findings. There were no significant differences in
eference diameter (2.7  0.6 mm vs. 2.7  0.6 mm, p 
.53) and percentage of diameter stenosis (24  9% vs. 22
Figure 2 Representative Images of the 3-Dimensional Integrate
Backscatter Intravascular Ultrasound in Patients With
(A) Patients with () metabolic syndrome (MetS); (B) patients without () MetS. T
52.7% in panel A and 23.0% in panel B. Blue and light blue  lipid pool; green a7%, p  0.43) between patients with or without MetS.
lso, in the conventional IVUS analysis, there were no
ignificant differences in various parameters between the 2
roups. However, IB-IVUS analysis indicated that the
atients with MetS were significantly increased in %LA
38  19% vs. 30  19%, p  0.02) and %LV (39  17%
s. 33 17%, p 0.03) and significantly decreased in %FV
57  14% vs. 61  13%, p  0.03). Figure 1 shows the
epresentative images of conventional IVUS and 2-
imensional IB-IVUS color-coded maps of coronary artery
laques in patients with MetS (Fig. 1A) or in patients
ithout MetS (Fig. 1B). The %LA and %FA were 46.1%
nd 50.1% in (Fig. 1A) and 12.1% and 80.9% in (Fig. 1B),
espectively. Figure 2 shows the representative images of 3D
B-IVUS color-coded maps of coronary artery plaques in
he patients with MetS (Fig. 2A) and in the patients
ithout MetS (Fig. 2B). The %LV and %FV were 52.7%
ithout MetS
rcentage of lipid volume was
low  fibrous lesion; red  high signal lesion.d
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Metabolic Syndrome and Plaque Characteristics March 20, 2007:1149–56nd 43.8% in (Fig. 2A) and 23.2% and 71.2% in (Fig. 2B),
espectively. The correlation of %LV and %FV measured by
physicians who conducted IVUS measurement indepen-
ently was r  0.95 (p  0.01) and r  0.93 (p  0.01),
espectively.
ssociation of MetS with tissue characteristics of coro-
ary plaque. On simple regression analysis, %LV and %FV
ere significantly correlated with UAP (r 0.197, p 0.02
nd r0.196, p 0.02), MetS (r 0.178, p 0.03 and
 0.179, p  0.03), and CRP levels (r  0.182, p 
.03 and r  0.184, p  0.03) (Table 3). A recent ACS
s the typical clinical presentation of vulnerable plaques
3,4,9). Also, the increase in %LA and the decrease in %FA
ave been reported as an important prerequisite for ACS
9). The optimal cutoff values of %LV and %FV for
redicting prevalence of UAP by receiver operating charac-
eristic analysis were 52% and 47%, respectively. In the
resent study, the lipid-rich plaque was thus clarified as
oth increase in %LV (52%) and decrease in %FV
imple Regression Analysis With Percentage Lipidolume or P rcentage Fibrous Volume As theependent Variable
Table 3
Simple Regression Analysis With Percentage Lipid
Volume or Percentage Fibrous Volume As the
Dependent Variable
Variable
Beta
Coefficient t Ratio p Value
Percentage lipid volume
Unstable angina 0.197 2.422 0.02
C-reactive protein 0.182 2.238 0.03
Metabolic syndrome 0.178 2.186 0.03
Multivessel disease 0.139 1.694 0.09
Old myocardial infarction 0.111 1.354 0.18
Statins 0.110 1.339 0.18
LDL cholesterol 0.096 1.160 0.25
Waist circumference 0.076 0.913 0.36
Age 0.070 0.851 0.40
Hypertension 0.053 0.643 0.52
Smoke 0.047 0.564 0.57
Triglycerides 0.043 0.518 0.60
Male 0.036 0.430 0.67
HDL cholesterol 0.028 0.341 0.73
Diabetes mellitus 0.027 0.327 0.74
Percentage fibrous volume
Unstable angina 0.196 2.414 0.02
C-reactive protein 0.184 2.260 0.03
Metabolic syndrome 0.179 2.194 0.03
Multivessel disease 0.134 1.637 0.10
Statins 0.112 1.359 0.18
Waist circumference 0.089 1.070 0.29
Old myocardial infarction 0.082 0.992 0.32
LDL cholesterol 0.078 0.950 0.34
Triglycerides 0.068 0.828 0.41
Age 0.064 0.773 0.44
Hypertension 0.063 0.767 0.44
Diabetes mellitus 0.051 0.617 0.54
Smoke 0.039 0.466 0.64
Male 0.029 0.350 0.73
HDL cholesterol 0.027 0.327 0.74DL  high-density lipoprotein; LDL  low-density lipoprotein.
a47%), which gave the significant association with the
ncidence of UAP (odds ratio 10.1, 95% confidence interval
.98 to 34.2, p  0.0002). Multivariate regression analysis
fter adjustment for confounding and non-MetS risk factors
howed that the prevalence of UAP and MetS remain
orrelated independently with %LV (r  0.314, p  0.0002
nd r  0.223, p  0.01) and %FV (r  0.273, p  0.002
nd r  0.206, p  0.02) (Table 4). On logistic regression
nalysis, individual risk factors of CVD did not show the
tatistical power to predict the lipid-rich plaque (data not
hown). Nevertheless, even after adjustment for confound-
ng and non-MetS risk factors, MetS identified by NCEP
TP III criteria (odds ratio 4.00, 95% confidence interval
.33 to 12.0, p  0.01) was proved to be an independent
redictor of the lipid-rich plaque (Table 5). Figure 3 shows
he lipid-rich plaque rate for individual risks with 0 to 2, 3
nd 4, or 5 component groupings of MetS. The lipid-rich
laque rate was significantly associated with an increasing
umber of MetS components in the grouping (p  0.002).
iscussion
etabolic syndrome, a common clinical problem with high
revalence, has been associated with adverse cardiovascular
isk and mortality, where ACS significantly affects mortal-
ultiple Regression Analysis With Percentage Lipidolume (r  0.40, p  0.01) or Percentage Fibrous37 3 as the Dependentariab
Table 4
Multiple Regression Analysis With Percentage Lipid
Volume (r  0.40, p  0.01) or Percentage Fibrous
Volume (r  0.37, p  0.03) as the Dependent
Variable
Variable
Beta
Coefficient t Ratio p Value
Percentage lipid volume (52%)
Unstable angina 0.314 3.783 0.0002
Metabolic syndrome 0.223 2.594 0.01
Statins 0.118 1.418 0.16
C-reactive protein 0.085 0.959 0.34
Percentage fibrous volume (47%)
Unstable angina 0.273 3.248 0.002
Metabolic syndrome 0.206 2.369 0.02
Statins 0.107 1.272 0.21
C-reactive protein 0.060 0.675 0.50
fter adjusting for confounding (age, gender, and body mass index), predefined (multivessel
isease and old myocardial infarction), and non-metabolic syndrome risk factors (smoking status
nd low-density lipoprotein cholesterol).
ogistic Regression Modelor Prediction of Lipid-Rich Plaque
Table 5 Logistic Regression Modelfor Prediction of Lipid-Rich Plaque
Variable
Odds
Ratio 95% CI p Value
Unstable angina 10.1 2.98–34.2 0.0002
Metabolic syndrome 4.00 1.33–12.0 0.01
Statins 0.37 0.13–1.07 0.07
C-reactive protein 1.40 0.83–2.40 0.21
fter adjusting for confounding (age, gender, and body mass index), pre-defined (multivessel
isease and old myocardial infarction), and non-metabolic syndrome risk factors (smoking status
nd low-density lipoprotein cholesterol).
CI  confidence interval.
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March 20, 2007:1149–56 Metabolic Syndrome and Plaque Characteristicsty, morbidity and quality of life in these patients (1,2). On
he other hand, evidence has accumulated that the lipid-rich
laque plays a critical role in the prevalence of ACS (3,4,9).
lso, the culprit lesion in patients with ACS has reportedly
hown to be a relatively minor stenosis (50% of the
ercentage diameter stenosis) (5,6). In the present study
sing IB-IVUS, the impact of MetS on tissue characteristics
f the coronary plaques with angiographically mild to
oderate coronary lesions was assessed, and our study found
hat MetS identified by NCEP ATP III criteria was
ignificantly associated with an increase in %LV and a
ecrease in %FV. The result suggested a high prevalence of
he lipid-rich plaque in these patients. Furthermore, MetS
as proved to be an independent predictor of lipid-rich
laque even after adjustment for confounding and non-
etS risk factors.
ndividual risk factors and coronary plaque characteris-
ics. The association of MetS with increasing atheroscle-
otic plaques is not surprising because individual compo-
ents of MetS have been well established as risk factors for
VD (15). However, few data are available for assessing the
orrelation between these risk factors and tissue character-
stics of coronary plaques. In the present study, individual
isk factors were not relevant to the lipid-rich plaque.
evertheless, patients with more than 3 clustering risks had
ignificantly increased lipid-rich plaque rates, which is
onsistent with a previous report (10) showing the syner-
istic effects of risk factors on atherosclerosis. In keeping
ith the building evidence on the role of inflammation in
VD, inflammatory factors have been shown as significant
redictors of atherosclerotic plaques (16–18). Nevertheless,
RP concentration was not significantly associated with the
ipid-rich plaque. Conversely, statin use was negatively
orrelated with the lipid-rich plaque, consistent with previ-
Figure 3 The Lipid-Rich Plaque Rate According
to Increasing Numbers of MetS Components
The lipid-rich plaque rate was significantly associated with an increasing num-
ber of metabolic syndrome (MetS) components in the grouping. p  0.002 by
analysis of variance (ANOVA).us reports (19,20) showing the beneficial effects of this qrug on plaque stability. Consequently, the lack of correla-
ion of lipid-rich plaque with CRP concentration suggests
ither that most of our included patients had ACS or that
hey were well treated with statins before the procedure.
mpact of MetS on coronary plaque characteristics. In
he present study, significant differences in the reference
iameter and the percentage diameter stenoses measured by
CA were not recognized between patients with and
ithout MetS. However, vessel volume and plaque volume
n the conventional IVUS analysis showed a tendency to
ncrease in patients with MetS compared with patients
ithout MetS. These results suggest that vessels in patients
ith MetS might be compensatorily enlarged to prevent
uilding atheroma from encroaching in lumen, thereby
oncealing the presence of a lesion when angiography is
erformed (21). In the IB-IVUS analysis, vessels in patients
ith MetS significantly increased in %LV and significantly
ecreased in %FV. This finding suggests the incidence of
ipid-rich plaque. Furthermore, on logistic regression, the
revalence of MetS was independently associated with
ipid-rich plaque. It has been reported that greater plaque
olume, including lipid-rich components, is relevant to
laque vulnerability, resulting in increasing coronary events.
aken together, these findings might explain the mecha-
isms of MetS contributing to the increasing risk of
ardiovascular events.
tudy limitations. This study has several limitations. First,
he lipid-rich plaque defined in the present study might not
e considered as a predominant marker of plaque vulnera-
ility. In addition, this definition was performed in the
tudy patients rather than a validation sample, raising the
ikelihood of a systematic error. Thus, we also arbitrarily
efined the cutoff point for the lipid-rich plaque as shown in
he previous report (22). Furthermore, the cutoff points
ere 49.3% for %LV and 49.2% for %FV, which were the
5th percentile of %LV and 25th percentile of %FV in the
resent study population. Following this definition, even
fter adjustment for confounding and non-MetS risk fac-
ors, MetS was again significantly correlated with %LV (r
.232, p  0.009) and %FV (r  0.225, p  0.01). Second,
he thrombus formation, which is often not detected even
ith gray-scale ultrasound, was not color coded and ana-
yzed by IB-IVUS. Angioscopic studies have revealed that
laque rupture and thrombus are present in 70% to 95% of
atients with ACS and 20% of those with stable angina
23,24). Thus, a combination of these modalities should be
ested to identify the vulnerable plaques in the future. Third,
he study sample was relatively small, and patients with
MI were not included. The prevalence of coronary plaque
haracteristics in patients with AMI or in patients without
VD remains to be evaluated. Fourth, data on cardiac
vents should be collected in future studies, because we used
cross-sectional study design. Together with other results,
ur findings need further study to answer a number of
uestions definitively.
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Metabolic Syndrome and Plaque Characteristics March 20, 2007:1149–56onclusions
ur findings indicate that MetS is significantly associated
ith lipid-rich plaque with mild to moderate coronary
esions. Furthermore, the prevalence of MetS has been
roved to be an independent predictor of the lipid-rich
laque even after adjustment for confounding and tradi-
ional and non-MetS risk factors. Together with other
esults, the study findings suggest that MetS identified by
ollowing NCEP ATP III criteria might be considered a
urrogate maker for early stages of coronary atherosclerosis,
specially in lipid-rich plaques, contributing to the increas-
ng risk of plaque vulnerability.
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